Shanghai MicroPort MedBot (Group) Co., Ltd. provided unaudited earnings guidance for the year ended 31 December 2022. The company expected that the revenue of the Company for the year ended 31 December 2022 would achieve a year-on-year growth of over 850% as compared to that for the year ended 31 December 2021 based on the preliminary review of the unaudited management accounts of the Group and the information available to the Company. For the purpose of pursuing on establishing a surgical robot technology innovation platform and industrial operation system, during the year ended 31 December 2022, the Group continued to maintain intensive inputs in the research and development, clinical registration, and commercialization activities.

Thus, despite the expected growth of revenue for the year ended 31 December 2022, the Company is expected to keep a loss-making trend for the year ended 31 December 2022 (the net loss is expected in the range of approximately RMB 1,100 million to approximately RMB 1,150 million).